Use of retinal procedures in medicare beneficiaries from 1997 to 2007

Archives of Ophthalmology

Volumn 128, Issue 10, 2010, Pages 1335-1340

  Ramulu, Pradeep Y ^a   Do, Diana V ^a   Corcoran, Kevin J ^c   Corcoran, Suzanne L ^c   Robin, Alan L ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Corcoran Consulting Group ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CRYOTHERAPY; DIATHERMY; DRUG IMPLANT; EPIRETINAL MEMBRANE; HUMAN; LASER COAGULATION; LOW LEVEL LASER THERAPY; MEDICAL SERVICE; MEDICARE; NEOVASCULARIZATION (PATHOLOGY); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINOPATHY; RETINOPEXY; SCLERA BUCKLING PROCEDURE; SCLEROTOMY; VITRECTOMY; CURRENT PROCEDURAL TERMINOLOGY; DRUG UTILIZATION; GOVERNMENT; HEALTH SERVICES RESEARCH; INJECTION; PHOTOCHEMOTHERAPY; RETINAL DISEASES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; VITREOUS BODY;

CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); CURRENT PROCEDURAL TERMINOLOGY; DRUG UTILIZATION; HEALTH SERVICES RESEARCH; HUMANS; INJECTIONS; LASER COAGULATION; PHOTOCHEMOTHERAPY; RETINAL DISEASES; RETROSPECTIVE STUDIES; SCLERAL BUCKLING; UNITED STATES; VITRECTOMY; VITREOUS BODY;

EID: 77957994849     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.224     Document Type: Article

References (37)

1. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
2. Muñoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118(6):819-825.
3. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485.
4. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36(1):182-191.
5. Cotter SA, Varma R, Ying-Lai M, Azen SP, Klein R; Los Angeles Latino Eye Study Group. Causes of low vision and blindness in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2006;113(9):1574-1582.
6. 2008 National Population Projections. US Census Bureau Web site. http://www.census.gov/population/www/projections/2008projections.html. Accessed November 3, 2009.
7. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
8. Kempen JH, O'Colmain BJ, Leske MC, et al; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552-563.
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1982;100(6):912-918. (Pubitemid 12119247)
10. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol. 1986;104(5):694-701.
11. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol. 1999;117(10):1329-1345.
12. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119(2):198-207.
13. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
14. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.
15. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142(1):1-9.
16. Beck RW, Edwards AR, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245-251.
17. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145(5):854-861.
18. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina. 2009;29(4):516-522.
19. Boscia F, Furino C, Dammacco R, Ferreri P, Sborgia L, Sborgia C. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol. 2005;15(1):89-95.
20. Arevalo JF, Maia M, Garcia-Amaris RA, et al; Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116(8):1481-1487.
21. Cervantes-Castañeda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol. 2009;19(4):622-629.
22. Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol. 2008;18(3):429-434.
23. Jardeleza MS, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24(2):87-92.
24. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucomawith intravitreal bevacizumab. Br J Ophthalmol. 2009;93(5):589-593.
25. D'Amico DJ. Clinical practice: primary retinal detachment. N Engl J Med. 2008;359(22):2346-2354.
26. Ramulu PY, Corcoran KJ, Corcoran SL, Robin AL. Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004. Ophthalmology. 2007;114(12):2265-2270.
27. de la Rúa ER, Pastor JC, Fernández I, et al. Non-complicated retinal detachment management: variations in 4 years: retina 1 project: report 1. Br J Ophthalmol. 2008;92(4):523-525.
28. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol. 2008;126(12):1748-1754.
29. Centers for Medicare and Medicaid Services Web site. www.cms.gov. Accessed December 23, 2009.
30. Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2009;(1):CD007324.
31. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110(8):1517-1525. (Pubitemid 36962483)
32. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
33. Arya AV, Emerson JW, Engelbert M, Hagedorn CL, Adelman RA. Surgical management of pseudophakic retinal detachments: ameta-analysis. Ophthalmology. 2006;113(10):1724-1733.
34. Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, Hilgers RD, Foerster MH; Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment Study Group. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. Ophthalmology. 2007;114(12):2142-2154.
35. Heimann H, Hellmich M, Bornfeld N, Bartz-Schmidt KU, Hilgers RD, Foerster MH. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment (SPR Study): design issues and implications. SPR Study report No. 1. Graefes Arch Clin Exp Ophthalmol. 2001;239(8):567-574.
36. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009;127(1):13-21.
37. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR; MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460-1469.